Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Susan Altschuller net worth and biography

Susan Altschuller Biography and Net Worth

CFO of Cerevel Therapeutics

Susan Altschuller, Ph.D., MBA has two decades of financial management, investor relations, and business planning experience with leading pharmaceutical and biotechnology companies. She has served as Cerevel’s Chief Financial Officer since May 2023. Most recently, she served as the chief financial officer of ImmunoGen, a biotechnology company developing the next generation of antibody-drug conjugates for cancer patients.

Before ImmunoGen, Dr. Altschuller worked at Alexion, where she was head of investor relations and later, head of enterprise finance. Prior to joining Alexion, Dr. Altschuller was head of investor relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen hemophilia spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. She received a BSE in Biomedical Engineering with Honors from Tulane University, a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management. She serves as Audit Chair on the board of directors of Vestaron Corporation and is a founding Board member of the HNRNP Family Foundation.

What is Susan Altschuller's net worth?: The estimated net worth of Susan Altschuller is at least $718,295.11 as of December 20th, 2023. Dr. Altschuller owns 16,913 shares of Cerevel Therapeutics stock worth more than $718,295 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Altschuller may own. Learn More about Susan Altschuller's net worth.
How old is Susan Altschuller?: Dr. Altschuller is currently 42 years old. There are 8 older executives and no younger executives at Cerevel Therapeutics. The oldest executive at Cerevel Therapeutics is Mr. Kenneth A. DiPietro, Chief Human Resources Officer, who is 65 years old. Learn More on Susan Altschuller's age.
How do I contact Susan Altschuller?: The corporate mailing address for Dr. Altschuller and other Cerevel Therapeutics executives is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. Cerevel Therapeutics can also be reached via phone at 844-304-2048 and via email at [email protected]. Learn More on Susan Altschuller's contact information.
Has Susan Altschuller been buying or selling shares of Cerevel Therapeutics?: Susan Altschuller has not been actively trading shares of Cerevel Therapeutics during the past quarter. Most recently, Susan Altschuller sold 13,808 shares of the business's stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $41.42, for a transaction totalling $571,927.36. Following the completion of the sale, the chief financial officer now directly owns 16,913 shares of the company's stock, valued at $700,536.46. Learn More on Susan Altschuller's trading history.
Who are Cerevel Therapeutics' active insiders?: Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.
Are insiders buying or selling shares of Cerevel Therapeutics?: In the last year, Cerevel Therapeutics insiders bought shares 4 times. They purchased a total of 6,462,597 shares worth more than $147,510,898.72. In the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 625,260 shares worth more than $21,054,440.60. The most recent insider tranaction occured on March, 4th when Director N Anthony Coles sold 50,000 shares worth more than $2,050,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company. Learn More about insider trades at Cerevel Therapeutics.
Information on this page was last updated on 3/4/2024.

Susan Altschuller Insider Trading History at Cerevel Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/20/2023	Sell	13,808	$41.42	$571,927.36	16,913

Susan Altschuller Buying and Selling Activity at Cerevel Therapeutics

Cerevel Therapeutics Company Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $42.47

$41.93

$42.49

50 Day Range

MA: $41.86

$40.88

$42.57

2 Week Range

Now: $42.47

$19.59

$43.59

Volume

679,080 shs

Average Volume

1,471,547 shs

Market Capitalization

$7.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Protect Yourself While There’s Still Time …

From Weiss Ratings | Ad